

Baxter

The Vest

AIRWAY CLEARANCE SYSTEM

THE CLEAR CHOICE



AIRWAY CLEARANCE WORKS

In multiple studies, airway clearance therapy with **The Vest** System has been shown to make a difference in health and quality of life for chronic respiratory patients.^{1,2} It has been demonstrated to reduce exacerbations and hospitalizations, and preserve pulmonary function for patients with a variety of conditions.^{3,4}

DISEASE STATES


- Bronchiectasis
- Neuromuscular disorders
- Cystic fibrosis
- And more

SYMPTOMS


- Evidence of retained secretions
- Difficulty with secretion clearance
- Atelectasis caused by mucus plugging

THE PIONEER IN CLEAR

The Vest System has been the trusted leader in High Frequency Chest Wall Oscillation (HFCWO) airway clearance therapy for more than 35 years.² No other HFCWO device has helped more respiratory patients—nearly 200,000—with their clearance needs.²



In HFCWO therapy, high-frequency oscillations are delivered to the airways to loosen secretions



Accelerated expiratory airflow thins and mobilizes secretions to the larger airways, where they can be cleared by coughing or suctioning




SETTING THE STANDARD

The **Vest** System is the leading airway clearance therapy for good reason. It has been studied more extensively than any other HFCWO device, as demonstrated in over 60 clinical trials.²



CYSTIC FIBROSIS


Preserved Pulmonary Function



Results from a four year clinical study comparing chest physiotherapy (CPT) to **The Vest** System showed improvement in FVC and FEV1 regression line slopes in 94% of CF patients who used **The Vest** Airway Clearance System after two years.⁴

BRONCHIECTASIS


Patient outcomes using HFCWO (pre- and post-HFCWO use). HFCWO may sustain improvements in clinical and economic outcomes for patients with bronchiectasis 3 years after receiving therapy³



Analysis of 73 patients with non-cystic fibrosis bronchiectasis who had received HFCWO therapy between 2009 and 2018, compared clinical and economic outcomes after 3 years of starting treatment. Results showed initiation of HFCWO therapy improved clinical and economic outcomes.³

NEUROMUSCULAR DISEASE

Neuromuscular patient outcomes (pre- and post-HFCWO use)⁵



Analysis of 426 patients with neuromuscular disease who received HFCWO therapy between 2007 and 2011, compared health care claims before and after HFCWO therapy intervention. Results of the study showed total medical costs, hospitalizations, and pneumonia claims were reduced after receiving HFCWO.⁵

RIGHT FOR YOUR PATIENTS

The **Vest** System combines proven performance with features designed to offer patients a comfortable therapy experience that fits their individual needs.



VERSATILE GARMENT DESIGN

- **Comfortable:** Breathable and soft to the touch
- **Convenient:** Machine washable and dryable, with stain-repellent finish
- **Colorful:** Available in Cashmere Rose, Coastal Blue, Calming Black, Color Me Purple, Cool Camo and Cute Camo*
- **Wrap garment** offers extended size options and versatility

**Not all colors are available in every garment size and style*

ON-THE-GO ACCESSORIES

- Lightweight roller bag is designed to fit in most airline overhead storage compartments
- One-bag system minimizes checked baggage issues when traveling



DESIGNED TO PERFORM

- Uniquely designed generator delivers comfortable, consistent air volume, for predictable airflow that increases as the frequency increases⁶
- Multiple programming options offer prescription flexibility
- Spanish interface option improves the therapy experience for Spanish-speaking patients and caregivers
- Cough Pause feature reminds patient to cough
- Garment reduces pressure when paused, to aid deep breathing
- Air hoses use simple press-and-twist action requiring minimal dexterity, and lock to prevent separation during treatment

THE CARE CONNEX PROGRAM FROM BAXTER

Baxter created the **CARE Connex** program to deliver comprehensive services at every step of the patient journey, offering new efficiencies for your practice and helping improve the therapy experience for your patients. We work with over a thousand leading local, regional and national companies to include commercial health plans and networks, Medicaid, Medicare, TRICARE and the Department of Veterans Affairs.



Insurance provider services



24/7 clinical care with multilingual customer service and product support



600+ in-home licensed clinical trainers



Continuing education courses



Clinical in-home assessments, trainings, outcomes monitoring and reporting



E-Prescribing available (Parachute, Epic, Cerner, Allscripts and others)

For more information, contact your Baxter Sales Representative or call us at **1-800-426-4224**.



Scan for **The Vest** System
Prescription Form

PLACE BUSINESS CARD HERE

Rx Only. For safe and proper use of product mentioned herein, please refer to the Instructions for Use or Operator Manual.

References

1. Langford V., Brooks B.R., Ward A., et al. High frequency chest wall oscillation therapy adherence on quality of life in patients with ALS/MND [Abstract]. The 21st International Symposium on ALS/MND, Orlando, FL, December 11-13, 2010; [CW240].
2. Data on file at Baxter International Inc.
3. Basavaraj A, Shah D, DeKoven M, et al. A Pre-Post Analysis Assessing the 3-Year Long-Term Impact of High Frequency Chest Wall Oscillation Therapy on Clinical Outcomes, Healthcare Cost and Utilization in Adult Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S. [Abstract]. *Am J Respir Crit Care Med*. 2021;203:A3944 and poster presented at ATS 2021.
4. Warwick W, Hansen L. The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. *Pediatr Pulmonol* 1991; 11: 265-271.
5. Lechtzin N, Wolfe LF and Frick KD. The Impact of High-Frequency Chest Wall Oscillation on Healthcare Use in Patients with Neuromuscular Diseases. *Ann Am Thorac Soc* 2016; 13 (6);904-9. DOI: 10.1513/AnnalsATS.201509-597OC.
6. Independent lab testing analyzed and compared average airflows at the mouth generated by high frequency chest wall oscillation (HFCWO) therapy in 10 subjects using home care garments. Airflows measured at commonly prescribed medium pressures (50% of maximum) at multiple therapy frequencies (5, 10, 15, and 20 Hz). Test data and reports on file at Baxter International Inc.

Baxter.com

Baxter International Inc.

One Baxter Parkway / Deerfield, Illinois 60015

Baxter, CARE Connex, Hillrom and The Vest are trademarks of Baxter International Inc.

US-FLC174-220004 [v3.0] 06/2024